The introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors has shown a reduction in hospitalizations for HF patients in the CANVAS [3] and EMPA-REG OUTCOME trials [4]. Here, SLC5A2 is linked to hydrops fetalis.